Alnylam Pharma (ALNY) Tops Q4 EPS by 64c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $266.11 +0.61%
Revenue Growth %: +15.3%
Financial Fact:
Other (expense) income: 229K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +15.3%
Financial Fact:
Other (expense) income: 229K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of $0.06, $0.64 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $593.16 million versus the consensus estimate of $580.61 million.
GUIDANCE:
Alnylam Pharma sees FY2025 revenue of $2.05-2.25 billion, versus the consensus of $2.68 billion.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- JPMorgan Upgrades Whitehaven Coal Ltd. (WHC:AU) (WHITF) to Overweight
- HII targets 15% shipbuilding throughput increase for U.S. Navy in 2026
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
